Klaria Pharma Holding AB (STU:6FN) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6FN Klaria Pharma Holding AB STU:6FN
15 GF Score
Price €0.05
GF Value €0.02
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Klaria Pharma Holding AB Defensive Interval Ratio?

STU:6FN
15GF Score
Klaria Pharma Holding AB STU:6FN
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Klaria Pharma Holding AB (STU:6FN) Overvalued in 2026?

Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued. The current stock price of €0.05 is trading 146% above its estimated GF Value™ of €0.02. GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.

Key valuation signals for STU:6FN:

  • Defensive Interval Ratio:
  • GF Value™: €0.02 vs. price of €0.05 (146% above fair value)
  • GF Score™: 15/100 with 8 warning signs

No single metric tells the full story. See the STU:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Klaria Pharma Holding AB Business Description

Other Exchanges KLAR:Sweden6FN:Germany
Address Virdings Alle 2, Uppsala, CHE, 754 50
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
15GF Score

Get the complete analysis for STU:6FN

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price
€0.02
GF Value